|
[Related PubMed/MEDLINE]
Total Number of Papers: 3465
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: PPI |
| Long Form |
: proton pump inhibitor |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
A Case of Gastric Mucormycosis in a 21-Year-Old Patient With Hemophagocytic Lymphohistiocytosis. |
EGD, HLH |
| 2 |
2023 |
Ambulatory pH-Impedance Findings Confirm that Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease. |
AET, GERD, LA, MNBI, PSPW |
| 3 |
2023 |
Bone microstructure in proton pump inhibitor users. |
Ct.vBMD, HR-pQCT |
| 4 |
2023 |
Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland. |
--- |
| 5 |
2023 |
Drug-Drug Interactions, Medication Adherence, and Stroke Should Be Considered When Approaching the Impact of Acid Suppression Therapy on Chronic Kidney Disease Patients. Comment on Chen et al. Impact of Acid Suppression Therapy on Renal and Survival Outcomes in Patients with Chronic Kidney Disease: A Taiwanese Nationwide Cohort Study. J. Clin. Med. 2022, 11, 5612. |
H2RA |
| 6 |
2023 |
Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial. |
AEs, BQT, H. pylori, HDDT, ITT, mITT, PP |
| 7 |
2023 |
Efficacy of laparoscopic Toupet fundoplication compared to endoscopic and surgical procedures for GERD treatment: a randomized trials network meta-analysis. |
APF, CrI, LTF, MSA, RCTs, RFA, TIF |
| 8 |
2023 |
Endoscopic Transoral Outlet Reduction for the Treatment of Biliary Reflux Symptoms in Patients After One-Anastomosis Gastric Bypass-a Case Series. |
BR, GERD-HRQL |
| 9 |
2023 |
Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases-STOPP/START-based study. |
CVDs, PIPs, PPOs |
| 10 |
2023 |
Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs. |
eGERD, GERD |
| 11 |
2023 |
Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden. |
SMRs |
| 12 |
2023 |
Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. |
LSS, MMF, MPA |
| 13 |
2023 |
Probability of additional intervention and long-term follow-up of esophagomyotomy. |
LHM, POEM |
| 14 |
2023 |
Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution. |
CREM, IFN, IL, pCREB, PHA, TSST-1, Zip |
| 15 |
2023 |
The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. |
HCC, ICIs, NSCLC, OS, PFS, RCC, SCC, UC |
| 16 |
2023 |
Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. |
--- |
| 17 |
2022 |
A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. |
CI, GERD, P-CAB, RR, TEAEs |
| 18 |
2022 |
A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients. |
H2RA, PHIS |
| 19 |
2022 |
A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy. |
PGI, UGIE |
| 20 |
2022 |
A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia. |
ACB |
| 21 |
2022 |
A rare endoscopic pattern in a patient with gastroesophageal reflux disease. |
--- |
| 22 |
2022 |
A review on lactoferrin as a proton pump inhibitor. |
LF |
| 23 |
2022 |
Acid Suppression and Antibiotics Administered during Infancy Are Associated with Celiac Disease. |
CD, H2RAs, HR |
| 24 |
2022 |
Acute interstitial nephritis observed with three different triggering agents. |
AIN, AKI, NSAIDs |
| 25 |
2022 |
An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding. |
--- |
| 26 |
2022 |
An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis. |
CIs, HRs, ICIs, OS, PFS |
| 27 |
2022 |
Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. |
BE, NSAID, OR, RE |
| 28 |
2022 |
Analysis of effects of laryngopharyngeal reflux disease and proton pump inhibitor treatment on Eustachian tube function in patients with obstructive sleep apnea hypopnea. |
BMI, ETS-7, LPRD, OSA |
| 29 |
2022 |
Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study. |
CRC, DOAC |
| 30 |
2022 |
Antireflux band mucosectomy: a novel minimally invasive approach for the treatment of refractory gastroesophageal reflux disease. |
ARBM, ARMS, TIF |
| 31 |
2022 |
Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. |
AET, GERD |
| 32 |
2022 |
Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria. |
GITU, GOPD |
| 33 |
2022 |
Assessment of the clinical and allergy profiles of PPI responsive and non-responsive eosinophilic esophagitis. |
EE, EoE, PPI-nr-EoE, PPI-r-EoE |
| 34 |
2022 |
Associated Mortality Risk of Proton Pump Inhibitor Therapy for the Prevention of Stress Ulceration in Intensive Care Unit Patients: A Systematic Review and Meta-analysis. |
CI, RCTs |
| 35 |
2022 |
Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. |
aOR, BPPV, CIs, ORs |
| 36 |
2022 |
Association between hospital-acquired pneumonia and proton pump inhibitor prophylaxis in patients treated with glucocorticoids: a retrospective cohort study based on 307,622 admissions in China. |
HAP |
| 37 |
2022 |
Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. |
--- |
| 38 |
2022 |
Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study. |
DDD, HCC |
| 39 |
2022 |
Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals. |
aOR, CIs |
| 40 |
2022 |
Association of Early Life Prescriptions for Antibiotics and Acid Suppressants with Childhood Psychotropic Prescriptions. |
aHR, H2RA |
| 41 |
2022 |
Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. |
MACE, PCI, STEMI |
| 42 |
2022 |
Autoimmune and immune-mediated inflammatory diseases after exposure to acid-suppressive medication: A systematic review and meta-analysis. |
H2RA, MC |
| 43 |
2022 |
Barriers to Guideline-Based Use of Proton Pump Inhibitors to Prevent Upper Gastrointestinal Bleeding. |
GI, PCPs |
| 44 |
2022 |
Bowel Habit Pattern of Patients with Self-Reported Constipation at Out Patient Department in North East Part of Bangladesh. |
--- |
| 45 |
2022 |
Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study. |
--- |
| 46 |
2022 |
Clinical efficacy of endoscopic antireflux mucosectomy vs. Stretta radiofrequency in the treatment of gastroesophageal reflux disease: a retrospective, single-center cohort study. |
ARMS, GEFV, GERD, GERD-HRQL, GerdQ, SRF |
| 47 |
2022 |
Clinical Endoscopic and Histologic Findings of a Long-Term Follow-Up (10.7 Years) After Roux-en-Y Laparoscopic Gastric Bypass: a Prospective Study. |
BE, BMI, GERD, LYGB |
| 48 |
2022 |
Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. |
--- |
| 49 |
2022 |
Clinical outcomes of asymptomatic low-grade esophagitis: results from a multicenter Chinese cohort. |
GERD |
| 50 |
2022 |
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. |
AEs, CI, HR, mCRC, ORR, OS, TTF |
| 51 |
2022 |
Clinical profile and characteristics of eosinophilic esophagitis patients presenting with refractory gastroesophageal reflux disease in Makassar, Indonesia. |
GERD |
| 52 |
2022 |
Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements. |
AET, GERD, RAM |
| 53 |
2022 |
Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. |
GERD, SAP |
| 54 |
2022 |
Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. |
--- |
| 55 |
2022 |
Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study. |
CIs, HRs |
| 56 |
2022 |
Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. |
GERD, MNBI, PSPWI |
| 57 |
2022 |
Clinical, histopathological features and efficacy of elimination diet and proton-pump inhibitor therapy in achieving histological remission in Asian children with eosinophilic gastritis. |
EG, FED, HPF |
| 58 |
2022 |
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. |
CDI, ICIs, IMDC |
| 59 |
2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. |
BQT, H. pylori, L-TT, M-TT |
| 60 |
2022 |
Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study. |
CI, H2RA, HR |
| 61 |
2022 |
Cost Analysis of Implementing an Exercise Program for Fall and Fracture Prevention in Older Adults on Proton Pump Inhibitor Therapy. |
--- |
| 62 |
2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. |
CV, GI, ICER, LDA, QALYs |
| 63 |
2022 |
Diagnostic thresholds and optimal collection protocol of salivary pepsin for gastroesophageal reflux disease. |
AM, GERD, PM |
| 64 |
2022 |
Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study. |
--- |
| 65 |
2022 |
Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis. |
CRC |
| 66 |
2022 |
Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. |
ROBINS-I, RRs |
| 67 |
2022 |
Dose-Dependent Proton Pump Inhibitor Exposure and Risk of Type 2 Diabetes: A Nationwide Nested Case-Control Study. |
cDDD, CI, OR, OR, T2DM, UGID |
| 68 |
2022 |
Drug treatment strategies for eosinophilic esophagitis in adults. |
EoE, STCs |
| 69 |
2022 |
Drug-Related Problems in Bariatric Surgery: a Retrospective Study. |
DRPs, NCC MERP, PFT |
| 70 |
2022 |
Early outcomes following EndoFLIP-tailored peroral endoscopic myotomy (POEM): the establishment of POEM services in two UK centers. |
EndoFLIP, FLIP, POEM |
| 71 |
2022 |
Effect of aluminum phosphate gel on prevention of early rebleeding after ligation of esophageal variceal hemorrhage. |
APG, EVB, EVL, PPI group |
| 72 |
2022 |
Effect of Proton Pump Inhibitor on the Outcome of Laryngeal Microsurgery in Patients With Vocal Fold Mucosal Disease With Reflux Symptoms. |
GRBAS, LMS, NHR, RSI, VF, VHI-10 |
| 73 |
2022 |
Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients. |
CI, HR, OS, PFS |
| 74 |
2022 |
Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). |
HDDT |
| 75 |
2022 |
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. |
CI, H. pylori, RR, VPZ |
| 76 |
2022 |
Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. |
HP, ITT, RR, VPZ |
| 77 |
2022 |
Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. |
DDD, GPs |
| 78 |
2022 |
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. |
CI, HR, iPFS, IPTW, OR, OS, UC |
| 79 |
2022 |
Effectiveness of Proton-Pump Inhibitors in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials. |
CIs, COPD, MD, RCTs, RRs |
| 80 |
2022 |
Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. |
CYP2C19, EM, H. pylori, PM, PPIs, RCTs |
| 81 |
2022 |
Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study. |
PA, pwCF |
| 82 |
2022 |
Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab. |
CI, HR, ICIs, OS, PFS |
| 83 |
2022 |
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. |
ICI, mRCC |
| 84 |
2022 |
Efficacy and safety of laparoscopic Roux-en-Y gastric bypass in symptomatic patients following fundoplication failure: a meta-analysis. |
BMI, GERD, LF, LRYGB, RLF |
| 85 |
2022 |
Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis. |
CI, GERD, GERD-HRQL, LES, RR |
| 86 |
2022 |
Eighteen-year-old man with syncope with Helicobacter pylori as the culprit: a case report. |
GI, H. pylori, PUD |
| 87 |
2022 |
Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. |
BQT, CI, H. pylori, ITT, PP |
| 88 |
2022 |
Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? |
H. pylori |
| 89 |
2022 |
Esophageal Microbiome in Healthy Children and Esophageal Eosinophilia. |
EE, EoE, RE |
| 90 |
2022 |
Esophagitis Dissecans Superficialis: A Frequently Missed and Rarely Reported Diagnosis. |
EDS |
| 91 |
2022 |
Establishing the Association Between Osteoporosis and Peptic Ulcer Disease: A Systematic Review. |
PMC, PUD, RCTs |
| 92 |
2022 |
Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study. |
CAD, CIs, H2RA, HRs |
| 93 |
2022 |
Factors associated with gastro-duodenal ulcer in compensated type 2 diabetic patients: a Romanian single-center study. |
--- |
| 94 |
2022 |
First-line therapies for H. pylori infection in Italy: a pooled-data analysis. |
--- |
| 95 |
2022 |
Fungal digestive enzymes promote macronutrient hydrolysis in the INFOGEST static in vitro simulation of digestion. |
GI, ONS |
| 96 |
2022 |
Gastric neuroendocrine tumor after prolonged use of proton pump inhibitor. |
NET |
| 97 |
2022 |
Gastrointestinal Bleeding Risk Factors in Patients with Type 2 Diabetes Mellitus. |
ASA, BMI, CHF, CKD, CVD, GIB, NOAC, NSAID |
| 98 |
2022 |
Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease. |
EPZ, GERD, P-CAB |
| 99 |
2022 |
High-dose proton pump inhibitors are associated with hospitalisation in bronchiectasis exacerbation. |
H2RA |
| 100 |
2022 |
Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients. |
H2RA |
|
A Search Service for Abbreviation / Long Form
